MGMT and glioblastoma: We left out survival data from 2 trials8,16 that exclusively recruited MGMT-methylated tumors (as they have significantly better survival), and from one trial with no control group.15 We found that our data on patients (age, male to female ratio, ECOG status, a proportion that underwent surgical resection, median- and 2-year survival) considered to be candidates for trial recruitment corresponded well with the patients that de facto had been participants in clinical trials for GBM (Table 3).